Navigation Links
OncoGenex Reports Third Quarter Financial Results
Date:11/4/2010

s in addition to our prior cash reserves provides us with approximately four years of cash, which we believe is sufficient to complete all three OGX-011/TV1011 (custirsen) Phase 3 trials including the Phase 3 trial in non-small cell lung cancer (NSCLC) that we expect to initiate next year."

"In addition, we now have the financial capacity to expand the OGX-427 program into a second randomized Phase 2 clinical trial. This proposed trial will evaluate OGX-427 in combination with standard chemotherapy as first-line treatment for metastatic bladder cancer, and will enroll approximately 180 patients," added Cormack. "Due to begin in 2011, this trial will complement the ongoing randomized Phase 2 clinical trial in prostate cancer, and Phase 1 clinical trial in superficial bladder cancer. Like custirsen, OGX-427 has broad potential for therapeutic benefit across a number of tumor types including bladder cancer, the fifth most common form of cancer. This underserved patient population is in desperate need of new treatment options." The Company reported a loss for the quarter ended September 30, 2010 of $6.9 million. As of September 30, 2010, cash and investment securities totalled $42.1 million. Together with the estimated $46.7 million proceeds from our October financing, and based on current and planned development activities, management believes existing cash and investment securities will provide adequate resources to fund the Company's currently planned operations into late 2014. Additional Recent Business Highlights

  • On November 2, 2010, the Company was notified that it had been awarded two grants totaling $489,000 under the Internal Revenue Service's Therapeutic Discovery Tax Credit Program. This program was created under the Patient Protection and Affordable Care Act of 2010 to provide tax credits or grants representing up to 50 percent of eligible qualified investments in therapeutic discovery projects during tax years 2009 and 2010. OncoGen
    '/>"/>

  • SOURCE OncoGenex Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related biology technology :

    1. OncoGenex Pharmaceuticals, Inc. Closes $50 Million Public Offering
    2. OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering
    3. OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering
    4. OncoGenex Pharmaceuticals to Present at the 9th Annual BIO Investor Forum
    5. TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER
    6. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
    7. OncoGenex Reports Second Quarter Financial Results
    8. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
    9. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
    10. OncoGenex Reports First Quarter Financial Results
    11. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/24/2014)... 24, 2014 -- A novel combination of microscopy and ... Energy,s Oak Ridge National Laboratory an unprecedented look at ... physical and electrochemical properties. , The research team ... the surface of a perovskite manganite, a complex material ... avenue to understand surface behavior could benefit researchers who ...
    (Date:7/24/2014)... 2014  Now available is a stem cell therapy ... Therapies , located in Guadalajara, Mexico ... a new health option: stem cell therapies for ... patients suffer from joint and muscle injuries due to ... torn rotator cuff, tennis elbow, and knee injuries. Throughout ...
    (Date:7/24/2014)...  ECC West Africa, LLC (ECC) signed a contract ... College Hospital (UCH) Ibadan Board of Management for the ... construct, and operate and maintain a new, state-of-the-art Cancer ... the first of the 4-phase project, ECC will conduct ... UCH Ibadan intends to finance and develop the Cancer ...
    (Date:7/24/2014)... leader Yung-Eun Sung has announced that they have ... graphenes which can be applied as high performance ... Sung is both a group leader at the ... Science* (IBS) and a professor at the Seoul ... with regards to the development of relative simplicity, ...
    Breaking Biology Technology:ORNL study reveals new characteristics of complex oxide surfaces 2Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2
    ... and for opening new food and beverage product categories ... 16 Frost & Sullivan, the international growth consulting ... 2008 North American Food and Beverage Probiotics Product Innovation ... strain, Ganeden BC30 (TM), for opening new development ...
    ... - The American Journal of Medicine , ... Medicine (AJM), one of Elsevier,s flagship health,sciences journals, has introduced ... forum where physicians and other,healthcare professionals can discuss the research ... Journal. , "The American ...
    ... Reduced Use of Chemicals Among Greatest Benefits , ... ... a few developing countries that have made significant progress in plant ... released, Dr. Elíbio Rech, a biotechnology researcher at Embrapa in Brazil, ...
    Cached Biology Technology:Ganeden Biotech Receives Frost & Sullivan 'Probiotics Product Innovation' Award 2Ganeden Biotech Receives Frost & Sullivan 'Probiotics Product Innovation' Award 3Elsevier Introduces The American Journal of Medicine Blog 2Elsevier Introduces The American Journal of Medicine Blog 3New Online Video Features Brazilian Researcher Elbio Rech 2New Online Video Features Brazilian Researcher Elbio Rech 3
    (Date:7/27/2014)... Microorganisms like bacteria and fungi can evade treatment by ... antifungal drugs. These permanent mutations were once thought to ... Now a new study has shown that microorganisms can ... as epimutations -- to gain the benefits of drug ... was discovered in a fungus called Mucor circinelloides, it ...
    (Date:7/25/2014)... 25, 2014 In the first broad-scale estimate of air ... and collaborators calculated that trees are saving more than ... of acute respiratory symptoms. , While trees, pollution removal ... than 1 percent, the impacts of that improvement are ... reduced air pollution at nearly $7 billion every year ...
    (Date:7/25/2014)... Boston, MA A study published online in the ... describes a novel approach to preventing cervical cancer based ... cervical cancer after removal of a discrete population of ... from a study that looked at squamocolumnar junction cells, ... canal and have been implicated as the origins of ...
    Breaking Biology News(10 mins):Scientists discover new, noncommittal mechanism of drug resistance 2Scientists discover new, noncommittal mechanism of drug resistance 3First national study finds trees saving lives, reducing respiratory problems 2Clearing cells to prevent cervical cancer 2
    ... at the UAB,s Institute of Environmental Science and Technology ... analysed the potential of different species of microalgae for ... the quantity of lipids per cell (essential for obtaining ... of marine algae that has received little attention till ...
    ... Human Frontier Science Program Organization (HFSPO) is awarding $34 ... competition for the HFSP Research Grants. Applicants went through ... that started with 715 submitted letters of intent. This ... scientists) together with 23 Program Grants (involving 81 scientists). ...
    ... associate a picture with a reward, the reward by ... monkeys, visual cortex. This finding was made by neurophysiologists ... Medical School) and American colleagues using functional brain scans ... Neuron . Our visual perception is not determined ...
    Cached Biology News:Microalgae could be a profitable source of biodiesel 2Impressive list of research teams for the 2013 HFSP Research Grants 2Reward linked to image is enough to activate brain's visual cortex 2
    Evi-1 Antibody Shipping Temperature: Cold Storage Temperature: -20C...
    ... contains the basic components required for the ... and recombinant mouse Dickkopf homolog-1 (Dkk-1) in ... contains sufficient materials to run ELISAs on ... following conditions are met: The assay ...
    The pCDF Expression System 1 plus Competent Cells contains 10 µg of pET-45b(+) DNA. pET-45b carries an N-terminal His•Tag ® coding sequence that is cleavable with enterokinase as well...
    ... Phosphorylase 1 ( Abpromise for all ... Synthetic peptide: MAATGANAEK AESHNDCPVR LLNPNIAKMK EDILYHFNLT TSRHNFPALF ... amino acids 1-99 of Human Uridine Phosphorylase ... 7378 Swiss Protein ...
    Biology Products: